Fenwick Sandra L 4

What Happened Sandra L. Fenwick, a Teladoc Health director (non-employee director under the issuer's plan), was awarded 30,441 restricted stock units (RSUs) on May 21, 2026. The grant is reported as a derivative award with an acquisition price of $0 — the RSUs represent contingent rights to receive common stock if and when they vest.

Key Details

• Transaction date: 2026-05-21; transaction code: A (award/grant).
• Amount: 30,441 RSUs; reported acquisition price: $0 (no cash paid).
• Each RSU = contingent right to one share of TDOC common stock (Footnote F1).
• Vesting: RSUs vest in full on the earlier of (i) May 21, 2027 or (ii) the day before Teladoc’s 2027 annual meeting (Footnote F2).
• Delivery: Vested shares will be delivered on the earliest of (i) within 90 days after a separation-of-service-based timing rule, (ii) immediately prior to/on/within 30 days following a Change of Control (per the Deferred Compensation Plan for Non-Employee Directors), or (iii) upon the reporting person’s death (Footnote F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported on Form 4 with a filing date of 2026-05-21 for a report period of 2026-05-21 — appears timely (no late filing indicated).
• No 10b5-1 plan, tax-withholding sale, or cashless exercise noted in this filing.

Context This is a standard director compensation award (an RSU grant) rather than a market purchase or sale. RSU grants do not immediately change voting shares outstanding until they vest and are settled; they are common for non-employee directors and should be interpreted as compensation, not necessarily as a direct signal of the director’s short-term view on the stock.